Datopotamab Deruxtecan, often abbreviated as DATO, represents an significant advancement regarding targeted cancer care. This novel antibody-drug conjugate combines a monoclonal antigen specifically targeting HER2 https://emilieitjy939440.aboutyoublog.com/profile